Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PureTech HealthCHIX:PRTCL +1.89%65 3-Year EBITDA Growth Rate is 5.80% as of Dec. 2025, which is 2220% above its 10-year median of 0.25. GuruFocus rates CHIX:PRTCL with a GF Score™ of 65/100 and a GF Value™ of £5.40 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,136 Biotechnology companies, PureTech Health ranks worse than 61.88% on this metric.
During the past 12 months, PureTech Health's average EBITDA Per Share Growth Rate was -267.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 5.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of PureTech Health was 13.20% per year. The lowest was -186.80% per year. And the median was 0.25% per year.
PureTech Health (CHIX:PRTCl) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
PureTech Health 3-Year EBITDA Growth Rate Related Terms
CHIX:PRTCL vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, PureTech Health's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PureTech Health 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PureTech Health's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where PureTech Health's 3-Year EBITDA Growth Rate falls into.
PureTech Health 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 5.80% mean?
PureTech Health (CHIX:PRTCL) has a 3-Year EBITDA Growth Rate of 5.80% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for PureTech Health and its competitors. This is 2220% above median its historical median of 0.25. According to the industry distribution chart, PureTech Health ranks #703 out of 1136 companies in the Biotechnology industry, placing it in the top 61.9%.
Is PureTech Health's 3-Year EBITDA Growth Rate too high?
PureTech Health's current 3-Year EBITDA Growth Rate of 5.80% is 2220% above median its 10-year median of 0.25. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. PureTech Health's value of 5.80% is 60.9% below this industry median. Based on the distribution chart, PureTech Health ranks #703 out of 1136 companies in the Biotechnology industry, which is below the industry midpoint. Overall, PureTech Health has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PureTech Health ranks #703 out of 1136 companies for 3-Year EBITDA Growth Rate. This places PureTech Health in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. PureTech Health's value of 5.80% is 60.9% below this benchmark. While the company's 10-year median is 0.25 vs. the industry median of 14.85, PureTech Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PureTech Health's current 3-Year EBITDA Growth Rate of 5.80% is 60.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for PureTech Health and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PureTech Health's current 3-Year EBITDA Growth Rate is 5.80%, which is 2220% above median its own 10-year median of 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (CHIX:PRTCL) is currently considered Possible Value Trap. The stock's GF Value™ is £5.40, compared to a current price of £1.18 — trading 78.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 5.80%, which is 2220% above median its 10-year median of 0.25 and 60.9% below the Biotechnology industry median of 14.85. PureTech Health's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For PureTech Health (CHIX:PRTCL), the current 3-Year EBITDA Growth Rate is 5.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PureTech Health (CHIX:PRTCL) Overvalued in 2026?
Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued.
The current stock price of £1.18 is trading 78.1% below its estimated GF Value™ of £5.40.
GuruFocus considers PureTech Health to be Possible Value Trap.
Key valuation signals for CHIX:PRTCL:
3-Year EBITDA Growth Rate: 5.80% (2220% above median its 10-year median of 0.25)
GF Value™: £5.40 vs. price of £1.18 (78.1% below fair value)
Industry Position: 60.9% below the Biotechnology median (#703 of 1136)
No single metric tells the full story. See the CHIX:PRTCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
65GF Score
Get the complete analysis for CHIX:PRTCL
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:PRTCL has been successfully added to your 
